- Weather delays final regattas in Louis Vuitton Cup
- Venezuela's Gonzalez Urrutia: from placeholder to opposition pointman
- Marquez thanks rain for San Marino MotoGP win as leader Martin pays for gamble
- Boeing, union reach preliminary deal to avert Seattle-area strike
- Neuville wins Acropolis Rally to close in on world title
- Venezuela's opposition figure fled to Spain to save 'his life'
- Trump, Harris tied on eve of televised presidential debate
- Paris Paralympics the greatest ever, say former Olympics executives
- Pope exit revives Sri Lanka's hopes in third Test against England
- Gunman kills 3 Israelis at West Bank crossing as Gaza war rages
- Marquez wins San Marino MotoGP as leader Martin pays for rain gamble
- Greece to hike fee for cruise passengers to Mykonos and Santorini
- Carsley's 'refreshing' England overhaul launches new era
- Typhoon Yagi weakens after leaving dozens dead in Vietnam, China, Philippines
- Swiss double in wheelchair marathons on final day of Paralympics
- France's Le Pen urges Macron to hold referendum to break deadlock
- Typhoon Yagi weakens, toll rises to 14 in Vietnam
- India's Randhir Singh elected Asian Olympic chief
- Under pressure, UN winds down 'unique' Iraq probe into IS crimes
- 'Proud' athletics great Weir calls time on marathon Paralympic career
- 'Brave' Afghanistan can beat anyone, says skipper ahead of NZ Test
- Vaughan warns England against 'taking the mick' after Sri Lanka collapse
- England's Moeen Ali retires from international cricket
- Japan's Hirata holds off inspired Smyth to win on Asian Tour
- China's Paralympic domination fails to ignite enthusiasm back home
- Venezuelan presidential opposition candidate heads for Spanish exile
- Sporting a feathered headdress, Pope finds 'Eden' in Papua New Guinea
- Super Typhoon Yagi toll rises to 9 in Vietnam after landslide
- Indonesian villagers dress corpses in ritual for the dead
- Williamson expects 'phenomenal' Root to keep breaking records
- The end of Olympic escapism for gloomy France
- Amy Adams gets real about motherhood in 'Nightbitch'
- Wallabies 'fell off cliff' in loss to Pumas, says coach Schmidt
- Venezuela says presidential opposition candidate has left country
- Women ride Pakistan's economic crisis into the workplace
- Wallabies 'fell of cliff' in loss to Pumas, says coach Schmidt
- Child abuse scandals hang over pope's East Timor visit
- Manhunt underway in US after Kentucky highway shooting
- Biden team, end in sight, keeps hope on Gaza truce despite setbacks
- Sabalenka dedicates US Open to family 'who never gave up' on dream
- Venezuela takes diplomatic jab at Brazil in spat over election
- Multiple people shot along highway in US state of Kentucky
- 'Super proud' Sabalenka downs Pegula to win US Open thriller
- In Papua New Guinea, Pope holds mass 'at the edge of the world'
- Hewett stays positive for wheelchair tennis despite agonising defeat
- Three things on US Open champion Aryna Sabalenka
- Sabalenka downs Pegula to win US Open thriller
- USA men land Paralympic basketball three-peat, Jiang takes 7th swim gold
- USA slump to first home defeat against Canada in 67 years
- Argentina hand Australia record 67-27 loss in Rugby Championship
Moderna sues Pfizer, BioNTech over Covid vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.
Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.
"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."
Pfizer pledged to "vigorously defend against the allegations of the lawsuit."
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.
The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.
O.Lorenz--BTB